1-3 of 3
Baolian Liu
Close
Sort by
Journal Articles

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7253–7254.
https://doi.org/10.1182/blood-2022-162856
Published: 2022
Journal Articles

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Sagar Lonial, MD FACP
Journal: Blood
Blood (2016) 128 (22): 2133.
https://doi.org/10.1182/blood.V128.22.2133.2133
Published: 2016
Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Ajay K Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 2142.
https://doi.org/10.1182/blood.V128.22.2142.2142
Published: 2016